Gut bacteria could be key to stopping cancer Drug's diarrhea side effect
NCT ID NCT07264985
First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 4 times
Summary
This study looks at why some breast cancer patients get diarrhea from the drug pyrotinib while others don't. Researchers will compare the gut bacteria of 60 patients who develop diarrhea with those who don't. They hope to find specific bacteria that protect against this side effect, which could lead to better ways to manage it in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pyrotinib
- What this could lead to
- If successful, this could point toward ways to predict or prevent severe diarrhea in breast cancer patients taking pyrotinib.
- What could go wrong
- This is a small, early observational study with no treatment being tested. It may not find clear links, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hubei Cancer Hospital
RECRUITINGWuhan, Hubei, 430079, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?